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Abstract
Telomerase is a key oncogenic enzyme, and a number of novel telomerase inhibitors are currently under develop-
ment. Because inhibition can be achieved either at the protein or at the enzymatic activity level, independent mea-
surements of these parameters are important in the development of effective therapeutic agents. In the current
study, we have developed a set of functional magnetic nanosensors capable of measuring the concentration of
telomerase, as well as its enzymatic activity in parallel. The method is based on a magnetic relaxation switch assay,
which can be performed in crude tissue samples and is fast and extremely sensitive. Using this method, we were
able to detect different amounts of telomerase protein and activity in various cancer and normal cell lines. Further-
more, we were able to study the effect of phosphorylation on telomerase activity. This system not only could pro-
vide a rapid assay for the evaluation of antitelomerase therapies but could also be implemented to the study of
other cancer markers.
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Introduction
Human telomerase (hTERT) is a ribonucleoprotein reverse transcrip-
tase that catalyzes the addition of telomeric repeat units (TTAGGG) to
the telomere’s end of each chromosome [1,2]. Most somatic cells do
not contain detectable levels of active telomerase; thus, their telomeres
shorten after each cell division. Once a critically short length of telo-
meric DNA is reached, the cells enter cell arrest and eventually die.
In contrast, telomerase activity is detectable in over 90% of known
human tumor cells, enabling these tumor cells to escape senescence
and to proliferate at a higher rate [3,4]. Thus, understanding telome-
rase biology and its complex regulation may shed light on how tumor
cells acquire their capability for unlimited replication (immortality).
Consequently, several therapeutic approaches to block telomerase ac-
tivity have been suggested [5]. The evaluation of all these novel thera-
pies mainly depends on a reliable measurement of both the amount
of telomerase protein and the enzymatic activity. Current technologies
to study telomerase biology involve polymerase chain reaction (PCR)
amplification for measuring telomerase activity [3,6] and Western
blots for measuring telomerase proteins [7]. Although highly sensitive,
these techniques are time-consuming and can be prone to false-positive
or false-negative results due to interferences and PCR artifacts [8]. In
addition, microarray methods for genomics and proteomics studies of
telomerase are difficult to perform due to the multiple components
required to measure enzyme activity.
Nanomaterials with unique magnetic and optical properties play
an increasingly important role in the design of molecular probes for
in vitro and in vivo diagnostics [9]. In particular, nanoparticle-based
assays that could quickly interrogate biologic systems and report on
the amount of a particular enzyme, its level of activation, and its rela-
tion to disease state would have a tremendous impact in medicine. Re-
cently, we have described the use of magnetic nanoprobes to sense for
telomerase activity through changes in T2 water relaxation [17]. We
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hypothesized that nanoparticle-based assays could be further refined to
allow simultaneous detection of protein levels and enzymatic activities.
For our experiments, one set of magnetic nanoparticles was con-
jugated to synthetic oligonucleotides complementary to TTAGGG
telomeric repeats, resulting in nanosensors able to measure telo-
merase activity (telomerase activity nanosensor). A second set was
conjugated to a polyclonal anti–hTERT antibody, resulting in a
nanosensor that detects telomerase protein (telomerase protein nano-
sensor; Figure 1). Using this dual nanosensor system, we were able to
detect different amounts of telomerase protein and, concomitantly,
measure telomerase activity in various cancer and normal cell lines.
Most importantly, we were able to assess the contribution of phos-
phorylation on telomerase activity.
Materials and Methods
Synthesis of Nanosensors
Anti–hTERT nanosensors. Aminated cross-linked iron oxide nano-
particles (CLIO-NH2 [10,11]) were conjugated to anti–hTER anti-
bodies through protein G (Sigma-Aldrich, St Louis, MO). First, to
conjugate protein G directly to magnetic nanoparticles, the aminated
magnetic nanoparticles were precipitated in isopropanol and redissolved
in DMSO to a concentration of 3.0 mg Fe/ml. Suberic acid bis(N -
hydroxysuccinimide ester, DSS; Sigma-Aldrich) was reacted with
250 μl of the aminated magnetic nanoparticles (3.0 mg Fe/ml) for
1 hour at room temperature (125 mM DSS final concentration).
The nanoparticles were washed three times by isopropanol precipita-
tion, followed by dissolution in 100 μl of phosphate-buffered saline
containing protein G (2 mg/ml). After an overnight incubation, the
protein G–conjugated nanoparticles were purified using a magnetic
separation column (Macs; Miltenyi Biotech, Auburn, CA) to separate
unbound protein. The number of protein G molecules attached to the
nanoparticle in solution was determined by a protein assay (Bradford
assay). Finally, 500 μl of the antitelomerase antibody solution (H-231,
3 mg/ml; Santa Cruz Biotechnology, Santa Cruz, CA) was added to the
protein G nanoparticle solution (500 μl, 1.5 mg Fe/ml) and incubated
overnight at 4°C before purification by magnetic separation and washed
with phosphate buffer (0.1 M pH 7.4). Typical final concentration of
the magnetic nanoparticle solution was 0.5 to 0.9 mg Fe/ml.
Telomerase activity nanosensors. Aminated cross-linked iron oxide
nanoparticles (CLIO-NH2) were conjugated to a telomeric repeat spe-
cific oligonucleotide (Tufts University Core Facility, Somerville, MA)
of sequence 5′-CCC-TAA-CCC-TAA-CCC-TAA-3′ [12,13] either
with the 3′ or 5′ end, resulting in two particles (Telo-1 and Telo-2). Re-
maining free oligonucleotides were removed by magnetic purification
of the Oligonucleotide-CLIO-NH2 (Miltenyi Biotec). Each CLIO par-
ticle had an average of four oligonucleotides bound. This number was
determined by adding to Telo-1 and -2 a Cy-5–labeled complementary
oligonucleotide (5′-TTA-GGG-TTA-GGG-3′) and by calculating the
molar amount of fluorochrome bound to the particles using the extinc-
tion coefficient of Cy-5 at 648 nm.
Cell Extracts
Cell extracts were prepared from various cell lines (B16 melanoma,
PC3 prostate cancer, hepatocellular carcinoma (HCC), 9L glioblas-
toma, E6-1 Jurkat lymphoma, OvCa ovarian carcinoma, and 5F rat
insulinoma) by incubating approximately 1 × 106 cells in 200 μl of
lysis buffer for 30 minutes on ice and then centrifuging at 12,000g
for 30 minutes [3]. Lysis buffer consisted of Tris-HCl (10 mM),
MgCl2 (1 mM), EGTA (1 mM), CHAPS (0.5%), and PMSF
(0.1 mM; all Sigma-Aldrich). Mouse tumor tissue samples of liver me-
tastasis were homogenized in lysis buffer. Aliquots of the supernatant
Figure 1. Schematic diagram for the magnetic nanosensor–based detection system. Cell lysates containing telomerase are incubated
with either the telomerase activity nanosensor or the anti–hTER nanosensor in solution. T2 relaxation time changes (induced by clus-
tering of nanoparticles; blue) are proportional to the levels of telomerase activity and amount of telomerase protein.
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were stored at −80°C. The protein concentration (BCA; Pierce,
Rockford, IL) varied between 0.5 and 4 mg/ml. For each telomerase
assay, 1 μg of protein was used. Normal human primary tissue mela-
nocytes were used as negative control and were a kind gift from Dr.
Mark Eller, Department of Dermatology, Boston University School of
Medicine [14–16]. To evaluate the state of telomerase activation by
phosphorylation, cell extracts from selected cell lines were incubated
at 37°C for 30 minutes in the presence or absence of 80 mU of protein
phosphatase 2A (PPA; Calbiochem, San Diego, CA) as described pre-
viously [17]. Telomerase activity was then determined as before.
Relaxation Time (T2) Measurements
T2 time relaxation measurements were carried out at 0.47 T and
40°C (Bruker NMR Minispec, Billerica, MA) in a total volume of
200 to 500 μl and with a final iron concentration of 10 μg Fe/ml
with 1 μg of cell extract protein in 500 μl after the particles were
incubated for 1 hour at 37°C. T2 values were obtained after adding
varying amounts of synthetic telomeric repeats to determine the sen-
sitivity of the assay. For magnetic resonance (MR) plate imaging, 50 μl
of the assay was transferred into a 384-well plate with an iron concen-
tration of 10 or 5 μg/ml (1:1 dilution). Plates were imaged in a 4.7-T
small animal magnetic resonance imager (Pharmascan, Bruker) using
T2-weighted spin-echo sequences with varying echo times to obtain a
T2 map (repetition time (T R), 2000 milliseconds; echo time (T E), 25
to 200 milliseconds) and a T1-weighted (T R, 600 milliseconds; T E,
30 milliseconds) spin-echo sequence. Image T2 analysis was performed
using OsiriX (www.osirix-viewer.com). A three-dimensional T2 image
was constructed by fitting of a standard exponential transverse re-
laxation model (M0exp(−T E/T2)) to stacks of spin-echo MR image
slices acquired at a T R of 2000 milliseconds and varying T E of 25
to 200 milliseconds. Renderings were performed at multiple angles
to highlight the resolution and three-dimensional nature of the calcu-
lated T2 maps. Data are shown as δT2 (T2 of the blank minus T2 of
sample) unless noted otherwise.
Western Blot
For Western blot analysis, tumor lysates were subjected to electro-
phoresis on SDS-PAGE followed by transfer to Hybond membrane
(Amersham Biosciences, Piscataway, NJ) according to the manufac-
turer’s instructions. Concentrations for blot analysis of anti-hTERT as
well as secondary antibodies varied according to the manufacturers’ rec-
ommendations (Santa Cruz Biotechnology; Jackson ImmunoResearch,
West Grove, PA). The blots were developed with the ECL system
(Amersham Biosciences). Immunoblot analysis of tubulin was used as
a loading control (Sigma).
Results
In the first set of experiments, we tested whether our anti–hTERT-
nanosensors can detect telomerase protein accurately and reproduc-
ibly. The nanosensors were synthesized by conjugating an anti–
hTERT antibody to dextran-coated iron oxide nanoparticles using
protein G. Because human telomerase is difficult to purify from cell
lysate [18] and purified telomerase is not commercially available, we
first established by Western blot analysis that the antibody selected
Figure 2. Validation of anti-hTERT and telomerase activity nanosensors. The amount of telomerase protein (hTERT) in various cell lines
was assessed by Western blot analysis (a), corrected for protein content and correlated to the changes in T2 (δT2) observed using the
developed anti-hTERT nanosensors (b). Telomerase activity determined by a commercial TRAP assay was correlated to the telomerase
activity measured using the telomerase activity nanosensors (c).
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for conjugation to the nanoparticles indeed recognizes a protein in
the size range of hTERT (120 kDa; Figure 2a) and compared the
δT2 obtained with our nanosensors to the Western blot analysis of
the telomerase present in various cell lines. Results show that the
observed δT2 in the magnetic assays correlated well with the data
obtained by Western blot (r2 = 0.9; Figure 2b). Next, we tested if
our parallel telomerase activity nanosensor were able to interrogate
telomerase activity (Figure 2c). Similar to the above described protein
sensor and in agreement with previous results [17], validation ex-
periments showed a tight fit between enzymatic activity measured
by a commercial quantitative telomerase repeat amplification proto-
col (TRAP) and magnetic nanosensor measurements (r2 = 0.9; Fig-
ure 2c). Taken together, these results confirm that the nanosensor
technology can indeed measure protein amounts and activity side
by side in a simple and miniaturized format.
We subsequently determined whether the above measurements for
telomerase protein can be made in parallel and at higher throughputs
with either direct MR imaging (Figure 3) or benchtop relaxometry
(Figure 4). We therefore analyzed eight different cell lysates from
normal and tumor cell lines in quadruplicate, together with a num-
ber of internal controls. The measurement time for all samples was
20 seconds with MR imaging, and the detected signal intensities
were very reproducible within the same cell line. No significant
δT2 were observed for the negative controls, as expected. All tumor
cell lines tested were positive for the presence of telomerase protein
at various levels, whereas primary skin melanocytes tested negative
(Figures 3 and 4). As a negative control, the corresponding cell ly-
sates were preincubated with the anti–hTERT antibody to block
the available hTERT epitopes before exposing them to the anti–
hTERT nanosensors, observing no significant detection of telome-
rase enzyme (T2 signal) as expected. To exclude that the nanoparti-
cles detected endogenous telomeric repeats already present in the
extracts, we performed additional controls where cell extracts were
either incubated with an unrelated primer or RNase experiments
Figure 3. δT2 map of telomerase protein (hTERT). Detection of telomerase protein using telomerase magnetic nanosensors was
achieved through MR imaging of wells in a 396-well plate (measurement time was 20 seconds for the 30 samples). Various cell lysates
were incubated with the nanosensors in quadruplicate. Insulinoma (5F); Prostate Cancer (PC-3); Melanoma (B16); Normal Human
Melanocytes; Lymphoma (E6-1); heat-denatured melanoma cell lysate served as a control. Lane 5 contains, as an additional control,
the corresponding cell lysates preincubated with anti–hTERT antibody before addition to hTERT protein sensor. The color bar indi-
cates to the left the change in T2 in milliseconds, to the right the relative amount of hTERT protein. The height of the well in the
three-dimensional graphic indicates the amount of δT2.
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where the nucleotides were left out or experiments where the cell ex-
tracts were preheated to destroy telomerase activity [17]. All these
controls did not result in a significant change in the T2 time after
incubating with the nanoparticles. Taken together, these results indi-
cate that the observed changes in T2 are due to the interaction of the
telomerase with the anti–hTERT antibody or the DNA on the par-
ticles and not due to nonspecific interaction with nontelomerase
components in the cell lysate. Furthermore, the analysis can be per-
formed rapidly with clinical MR scanners as shown in Figure 3.
We next compared levels of telomerase protein and telomerase ac-
tivity within the same cell lines (Figure 4). Results show that HCC
cells had the highest level of telomerase activity, whereas the mela-
noma cell line had a significantly lower telomerase activity. However,
a higher amount of telomerase protein was present in the melanoma
cell line compared to the HCC cell line. Also, a significantly lower
amount of telomerase protein was present in insulinoma compared to
lymphoma, whereas telomerase activity was much higher in the for-
mer. These observed discrepancies in protein levels and enzymatic
activity are in line with previous reports that show that telomerase
has different activation states. It has been shown that higher activity
levels are necessary for sustained malignant growth and aggressiveness
(ability to metastasize) [19–22]. These results indicate that telome-
rase can be present at different levels of activation and that measur-
ing either telomerase activity or its activation alone might not be
sufficient to obtain accurate information on the telomerase status
of a given tumor.
We next investigated the apparent difference between the amount
of hTERT protein and telomerase activity in the above mentioned
cell lines. Specifically, we investigated the effects of phosphorylation
by measuring the decrease in telomerase activity (indicated by δT2)
upon incubation with PPA. The observed δT2 after PPA incubation
should reflect the different native phosphorylation states of telome-
rase in these cell lines. As expected, different levels of activation of
telomerase by phosphorylation were observed, ovarian and breast
cancer cell lines having the most phosphatase-sensitive telomerase ac-
tivity, which suggests that the telomerase in these cell lines is mostly
activated by phosphorylation (Figure 5a). Interestingly, in the mela-
noma cell lines studied, phosphorylation also seems to play a role in
the activation of the telomerase protein, although not as pronounced
as in ovarian and cancer cells, which suggests different mechanisms
in different cell lines.
Discussion
The nanosensensor technology described here is based on mag-
netic nanoparticle conjugates, which form nanoclusters on target in-
teraction. The nanocluster formation (typically 300-500 nm) causes
a rapid decrease in the water T2 relaxation time [13]. Because of the
inherently built-in amplification (each cluster formation affects bil-
lions of surrounding water molecules), the ability to sense in turbid
samples and the ability to design different assay configurations
(DNA, RNA, protein, metabolites), this method provides unique
advantages. Water relaxation can be readily detected by benchtop
relaxometers [23] chemical nuclear magnetic resonance (NMR) sys-
tems, or even magnetic resonance imaging systems [17,24]. In this
study, we evaluated whether parallel measurements could be made
to determine protein levels and protein activity in biologic samples
using the same readout, the proportional decrease in T2 (δT2). As a
clinically relevant model system, we used telomerase, a protein impli-
cated in tumorigenesis, whose functional state is affected differently
by a number of drugs currently under development [25]. We show
that the developed technology can quickly and accurately determine
the amount of telomerase protein and assess for its levels of activity
and activation.
Figure 4. Correlation between amount of telomerase protein and telomerase activity. Detection of amount of telomerase protein (a) and
telomerase activity (b) in various cell lysates using the telomerase magnetic nanosensors and a benchtop relaxometer. No correlation
between telomerase activity and amount of telomerase protein was observed. Normal human melanocytes were used as control given
their low amounts of telomerase protein and telomerase activity. Note the increase in both amount and activity of telomerase in mela-
noma, compared to melanocytes. Additional controls included heat inactivated cell lysates, addition of an unrelated primer not recog-
nized by hTERT, leaving out the nucleotides or adding RNase.
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High levels of hTERTmRNA have been observed in most tumors
with high telomerase activity [26], suggesting that hTERT is by itself
an up-regulating factor in its own activation, essential in oncogenesis,
tumor progression, and tumor invasion [27]. However, some lesions
and normal tissue with low or undetectable telomerase activity have
been found to contain significant levels of hTERT mRNA, pre-
sumably due to either alternate splicing [28] or posttranslational
modifications such as phosphorylation-dephosphorylation [17,29–
31] that might alter the activity of the enzyme. Most importantly,
high levels of telomerase activity have been reported in aggressive tu-
mors and in metastatic lesions presumably due to up-regulation of
telomerase reverse transcriptase [32]. However, the effect of phos-
phorylation on the telomerase activity of these metastatic lesions is
not well understood at this time.
On the basis of our results, the measured activity of telomerase has
two main components: 1) the contribution from the total amount of
telomerase protein and 2) the level of phosphorylation of telomerase
protein. When both of these parameters are taken into account by
multiplying the detected amount of telomerase protein (as the δT2
protein) with the amount of phosphorylation-induced activation
of telomerase (δT2 activation) and plotted against the measured
telomerase activity (δT2 activity), a linear correlation was observed
(Figure 5b). This observation has important implications for the eval-
uation of novel antitelomerase therapies because both the level of ac-
tivation and the amount of hTERT protein must be taken into
account. It is thus highly advisable to determine not only the ac-
tivity but also the amount of protein to determine whether a given
telomerase activity level is either due to highly activated telomerase
present in small amounts or to large amounts of less active enzyme,
because this could have important implications for an antitelomerase-
geared therapy.
In summary, we have developed an integrated nanosensor tech-
nology to determine the levels of a neoplastic protein marker (telo-
merase) and its level of activation in various cancer cells lines. With
this method, results can be obtained more quickly, thereby using the
same nanoparticle technology platform, instead of laborious and
costly methods such as reverse transcription–PCR and Western blots.
The method can be easily adapted to study other cancer-related pro-
tein markers such as metalloproteinases and caspases, among others.
Current developments in NMR miniaturization [33] and portable
relaxometers [34] will facilitate the implementation of the described
technique in future cancer diagnostics, prognostics, and the assess-
ment of antitelomerase-geared therapies.
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